Skip to main content
NCBI home page
BMC Cancer logoLink to BMC Cancer
. 2024 Jan 23;24:114. doi: 10.1186/s12885-024-11863-0

Correction: Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer

Elif Şenocak Taşçı 1,✉, Başak Oyan 2, Özlem Sönmez 2, Arda Ulaş Mutlu 2, Muhammed Mustafa Atcı 3, Abdullah Sakin 4, İrem Öner 5, Havva Yeşil Çınkır 6, Melek Karakurt Eryılmaz 7, Dilek Çağlayan 7, Onur Yazdan Balçık 8, Nail Paksoy 9, Senem Karabulut 10, Derya Kıvrak Salim 11, Cemil Bilir 12, Miraç Özen 13, Melike Özçelik 14, Ali Arıcan 2, Baran Akagündüz 15, Ali İnal 16, Dinçer Aydın 17, Leyla Özer 2, Ahmet Gülmez 18, Nazım Serdar Turhal 19, Selin Aktürk Esen 20, Efnan Algın 20, Sinem Akbaş 21, Yakup İriağaç 22, Teoman Şakalar 23, Çağlar Ünal 24, Özlem Er 2, Şaban Seçmeler 25, Mustafa Bozkurt 2
PMCID: PMC10804792  PMID: 38262962

Correction: BMC Cancer 24, 16 (2024)

10.1186/s12885-023-11783-5

Following publication of the original article [1], the authors reported an error in the affiliations of authors Başak Oyan, Özlem Sönmez, Leyla Özer, Ali Arıcan, Özlem Er and Mustafa Bozkurt. These authors are all affiliated to institution 2.

The original article [1] has been corrected.

Footnotes

The online version of the original article can be found at 10.1186/s12885-023-11783-5.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  • 1.Taşçı EŞ, Oyan B, Sönmez Ö, et al. Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer. BMC Cancer. 2024;24:16. doi: 10.1186/s12885-023-11783-5. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from BMC Cancer are provided here courtesy of BMC

RESOURCES